| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1001/JAMA.1996.03540080037026 |
| P698 | PubMed publication ID | 8773633 |
| P2093 | author name string | J A Smith | |
| P T Scardino | |||
| P F Schellhammer | |||
| G S Gerber | |||
| M Ohori | |||
| A W Middleton | |||
| G W Chodak | |||
| D F Paulson | |||
| F H Schroeder | |||
| R A Thisted | |||
| D B Rukstalis | |||
| H G Frohmuller | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 615-619 | |
| P577 | publication date | 1996-08-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Results of radical prostatectomy in men with clinically localized prostate cancer. | |
| P478 | volume | 276 |
| Q41186407 | A decision analysis for treatment of clinically localized prostate cancer |
| Q40614060 | A population-based study on management of prostate cancer in four regions of France. |
| Q53219870 | A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. |
| Q28484126 | An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account |
| Q39227841 | Analysis and presentation. Clinical trials on prostate cancer |
| Q33620512 | Canine prostate: contrast-enhanced US-guided radiofrequency ablation with urethral and neurovascular cooling--initial experience |
| Q82209769 | Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy |
| Q41649061 | Conformal proton therapy for early-stage prostate cancer |
| Q33979664 | Current challenges in cancer screening. Part II. Prostate cancer screening |
| Q39872525 | DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction |
| Q81348926 | Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer |
| Q42679462 | Development and Validation of Preoperative Nomogram for Disease Recurrence Within 5 Years After Laparoscopic Radical Prostatectomy for Prostate Cancer |
| Q39794124 | Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy |
| Q44199125 | Does age influence the behaviour of localized prostate cancer? |
| Q35093095 | Early prostate cancer: clinical decision-making |
| Q38413647 | Endothelin‐1: a predictor of extracapsular extension in clinically localized prostate cancer? |
| Q39101615 | First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients. |
| Q44519352 | HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study |
| Q42234980 | High-grade prostate cancer: favorable results in the modern era regardless of initial treatment |
| Q47399759 | Impact of biochemical failure on long-term clinical outcome after radical prostatectomy for prostate cancer in Japan |
| Q38764787 | Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease |
| Q81556609 | Important preoperative prognostic factors for extracapsular extension, seminal vesicle invasion and lymph node involvement in cases with radical retropubic prostatectomy |
| Q61993852 | Improving the quality of life of patients with prostate carcinoma |
| Q43362389 | Incontinence After Prostatectomy: Coping With Incontinence After Prostate Cancer Surgery |
| Q38232407 | Interstitial photodynamic therapy for prostate cancer: a developing modality |
| Q42765839 | Localised prostate cancer: can we do better? There have been some advances in local control, but little impact on survival |
| Q55392880 | Localized prostate cancer: early intervention or expectant therapy? |
| Q87258499 | Long-term outcome following radical prostatectomy for Gleason 8-10 prostatic adenocarcinoma |
| Q36042296 | Long-term outcome of detectable PSA levels after radical prostatectomy |
| Q75238008 | Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization |
| Q33965472 | Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen |
| Q30310352 | Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients |
| Q34034684 | PSA screening: the bottom line |
| Q40868258 | Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer |
| Q40993274 | Perineural invasion status, Gleason score and number of positive cores in biopsy pathology are predictors of positive surgical margin following laparoscopic radical prostatectomy |
| Q52893498 | Population-based study of long-term survival in patients with clinically localised prostate cancer. |
| Q39530354 | Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria |
| Q34861472 | Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score |
| Q30471137 | Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation |
| Q34804009 | Prostate cancer and health-related quality of life: a review of the literature. |
| Q34029755 | Prostate cancer: 2. Natural history. |
| Q44184008 | Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer register. South-East Region Prostate Cancer Group |
| Q73784692 | Quality control of radical prostatectomy: a feasibility study |
| Q41450504 | Radical prostatectomy: consideration of the risk factors |
| Q35734373 | Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer |
| Q41862911 | Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum |
| Q31811708 | Role of stimulatory guanine nucleotide binding protein (GSalpha) in proliferation of PC-3M prostate cancer cells |
| Q42264405 | Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy |
| Q80273352 | Study of prostate cancer pathologic features in Chinese populations |
| Q44847025 | Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. |
| Q33958709 | The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. |
| Q34037487 | The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model |
| Q37054328 | The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis |
| Q77839118 | The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men |
| Q34037498 | The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model |
| Q36090379 | The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer |
| Q34097583 | The role of active treatment in early prostate cancer |
| Q35164656 | Treatments for improving survival of patients with prostate cancer |
| Q31536892 | Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry |
| Q36364398 | Watchful waiting for prostate cancer: a review article |
| Q40666159 | Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy. |
Search more.